The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Research Report 2025
Synopsis
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
The global Selective Serotonin Reuptake Inhibitors (SSRIs) market was valued at US$ 4788 million in 2023 and is anticipated to reach US$ 6118 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
This report aims to provide a comprehensive presentation of the global market for Selective Serotonin Reuptake Inhibitors (SSRIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Selective Serotonin Reuptake Inhibitors (SSRIs).
Report Scope
The Selective Serotonin Reuptake Inhibitors (SSRIs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Selective Serotonin Reuptake Inhibitors (SSRIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Selective Serotonin Reuptake Inhibitors (SSRIs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Segment by Application
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
The global Selective Serotonin Reuptake Inhibitors (SSRIs) market was valued at US$ 4788 million in 2023 and is anticipated to reach US$ 6118 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.
This report aims to provide a comprehensive presentation of the global market for Selective Serotonin Reuptake Inhibitors (SSRIs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Selective Serotonin Reuptake Inhibitors (SSRIs).
Report Scope
The Selective Serotonin Reuptake Inhibitors (SSRIs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Selective Serotonin Reuptake Inhibitors (SSRIs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Selective Serotonin Reuptake Inhibitors (SSRIs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.
Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)
Segment by Application
Depression
Anxiety and panic disorder
Other mental conditions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Citalopram (Celexa)
1.2.3 Escitalopram (Lexapro)
1.2.4 Fluoxetine (Prozac)
1.2.5 Paroxetine (Paxil, Pexeva)
1.2.6 Sertraline (Zoloft)
1.2.7 Vilazodone (Viibryd)
1.3 Market by Application
1.3.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Depression
1.3.3 Anxiety and panic disorder
1.3.4 Other mental conditions
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Perspective (2019-2030)
2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Growth Trends by Region
2.2.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Historic Market Size by Region (2019-2024)
2.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Forecasted Market Size by Region (2025-2030)
2.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Dynamics
2.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Industry Trends
2.3.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Drivers
2.3.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Challenges
2.3.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Selective Serotonin Reuptake Inhibitors (SSRIs) Players by Revenue
3.1.1 Global Top Selective Serotonin Reuptake Inhibitors (SSRIs) Players by Revenue (2019-2024)
3.1.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue Market Share by Players (2019-2024)
3.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue
3.4 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Concentration Ratio
3.4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Selective Serotonin Reuptake Inhibitors (SSRIs) Revenue in 2023
3.5 Selective Serotonin Reuptake Inhibitors (SSRIs) Key Players Head office and Area Served
3.6 Key Players Selective Serotonin Reuptake Inhibitors (SSRIs) Product Solution and Service
3.7 Date of Enter into Selective Serotonin Reuptake Inhibitors (SSRIs) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Selective Serotonin Reuptake Inhibitors (SSRIs) Breakdown Data by Type
4.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Historic Market Size by Type (2019-2024)
4.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Forecasted Market Size by Type (2025-2030)
5 Selective Serotonin Reuptake Inhibitors (SSRIs) Breakdown Data by Application
5.1 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Historic Market Size by Application (2019-2024)
5.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2019-2030)
6.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2019-2024)
6.4 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2019-2030)
7.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2019-2024)
7.4 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2019-2030)
8.2 Asia-Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2019-2024)
8.4 Asia-Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2019-2030)
9.2 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2019-2024)
9.4 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size (2019-2030)
10.2 Middle East & Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2019-2024)
10.4 Middle East & Africa Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan Plc
11.1.1 Allergan Plc Company Detail
11.1.2 Allergan Plc Business Overview
11.1.3 Allergan Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
11.1.4 Allergan Plc Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2019-2024)
11.1.5 Allergan Plc Recent Development
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Detail
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
11.2.4 Eli Lilly and Co. Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2019-2024)
11.2.5 Eli Lilly and Co. Recent Development
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Detail
11.3.2 GlaxoSmithKline Plc Business Overview
11.3.3 GlaxoSmithKline Plc Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
11.3.4 GlaxoSmithKline Plc Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2019-2024)
11.3.5 GlaxoSmithKline Plc Recent Development
11.4 H. Lundbeck AS
11.4.1 H. Lundbeck AS Company Detail
11.4.2 H. Lundbeck AS Business Overview
11.4.3 H. Lundbeck AS Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
11.4.4 H. Lundbeck AS Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2019-2024)
11.4.5 H. Lundbeck AS Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Selective Serotonin Reuptake Inhibitors (SSRIs) Introduction
11.5.4 Pfizer Inc. Revenue in Selective Serotonin Reuptake Inhibitors (SSRIs) Business (2019-2024)
11.5.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
